Table 3. Alterations of Invasion- and Metastasis-Related Genes Identified Using Microarray of Genistein-Treated HCC1395 Breast Cancer Cells

Supplementary Table 7. Genes whose expression exhibited a dramatic peak or valley in one sample (i.e.  only in one tissue at one stage) relative to all others. 109 genes represent transiently expressed effectors of developmental choices. Of these  22 were detectable (present) only in the sample where expression was upregulated and were not detectable (absent) in all other samples. A total of 18 were detectable in all samples except the one where expression was downregulated

Supplementary Table 4. We identified genes that were either up- or downregulated in at least one IE sample relative to at least one NIE sample by twofold or more with an FDR of ≤0.5%. This resulted in the identification of 1410 genes that were upregulated and 226 genes that were downregulated in three or more (at least 10%) of all IE samples; Middle (M) Analysis

Supplementary Table 4. We identified genes that were either up- or downregulated in at least one IE sample relative to at least one NIE sample by twofold or more with an FDR of ≤0.5%. This resulted in the identification of 1410 genes that were upregulated and 226 genes that were downregulated in three or more (at least 10%) of all IE samples; Late (L) Analysis

Supplementary Table 4. We identified genes that were either up- or downregulated in at least one IE sample relative to at least one NIE sample by twofold or more with an FDR of ≤0.5%. This resulted in the identification of 1410 genes that were upregulated and 226 genes that were downregulated in three or more (at least 10%) of all IE samples; EML Analysis

Table 1. Genes showing significant different responses for the treatment with glycyrrhizin from those with E2 and the extract of G. glabra

Table 2. Molecular Function of 95 Predictor Genes

Table 1. Differentially expressed genes from microarray analyses I and II

Table 1. Differential expression of chemokines/chemokine receptors and ILs/IL receptors between metastatic versus nonmetastatic SCCHN